Daniela Hernandez

2.4k total citations
16 papers, 447 citations indexed

About

Daniela Hernandez is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Daniela Hernandez has authored 16 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Daniela Hernandez's work include Acute Myeloid Leukemia Research (9 papers), IL-33, ST2, and ILC Pathways (5 papers) and Eosinophilic Esophagitis (4 papers). Daniela Hernandez is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), IL-33, ST2, and ILC Pathways (5 papers) and Eosinophilic Esophagitis (4 papers). Daniela Hernandez collaborates with scholars based in United States, Germany and France. Daniela Hernandez's co-authors include Chiara Romagnani, Mark J. Levis, Richard J. Jones, Christina Stehle, Gabriel Ghiaur, Meng Su, Trivikram Rajkhowa, Yu‐Ting Chang, Sanjay Mohan and Hugo F. Fernández and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Blood.

In The Last Decade

Daniela Hernandez

16 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Hernandez United States 10 209 191 138 116 53 16 447
Iwona Konieczna United States 8 86 0.4× 279 1.5× 92 0.7× 93 0.8× 36 0.7× 13 501
Alexander Platz Germany 7 156 0.7× 116 0.6× 121 0.9× 29 0.3× 69 1.3× 9 357
Marina Lesnikova United States 11 253 1.2× 186 1.0× 88 0.6× 51 0.4× 55 1.0× 31 416
Laura Todt United States 6 264 1.3× 147 0.8× 123 0.9× 52 0.4× 49 0.9× 8 432
Carmen Herrero-Sánchez Spain 7 204 1.0× 132 0.7× 121 0.9× 20 0.2× 55 1.0× 8 346
Hannah Cullup United Kingdom 11 272 1.3× 280 1.5× 55 0.4× 30 0.3× 36 0.7× 15 436
Stephan Bohl Germany 8 159 0.8× 89 0.5× 176 1.3× 20 0.2× 39 0.7× 16 329
Silvia Gimondi Italy 5 175 0.8× 118 0.6× 57 0.4× 33 0.3× 43 0.8× 10 267
Stephan Schulz United States 2 165 0.8× 293 1.5× 44 0.3× 44 0.4× 29 0.5× 2 404
Il‐Kyoo Park United States 7 90 0.4× 297 1.6× 94 0.7× 28 0.2× 37 0.7× 10 420

Countries citing papers authored by Daniela Hernandez

Since Specialization
Citations

This map shows the geographic impact of Daniela Hernandez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Hernandez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Hernandez more than expected).

Fields of papers citing papers by Daniela Hernandez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Hernandez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Hernandez. The network helps show where Daniela Hernandez may publish in the future.

Co-authorship network of co-authors of Daniela Hernandez

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Hernandez. A scholar is included among the top collaborators of Daniela Hernandez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Hernandez. Daniela Hernandez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hernandez, Daniela & Christina Stehle. (2022). Embryonic ILC-poiesis across tissues. Frontiers in Immunology. 13. 1040624–1040624. 5 indexed citations
2.
Pratz, Keith W., Jason Kaplan, Moshe Levy, et al.. (2022). A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 108(3). 705–716. 10 indexed citations
3.
Reguant, Anna Pascual, Ralf Köhler, Ronja Mothes, et al.. (2021). Multiplexed histology analyses for the phenotypic and spatial characterization of human innate lymphoid cells. Nature Communications. 12(1). 1737–1737. 22 indexed citations
4.
Hernandez, Daniela, Kerstin Juelke, Pawel Durek, et al.. (2021). An in vitro platform supports generation of human innate lymphoid cells from CD34+ hematopoietic progenitors that recapitulate ex vivo identity. Immunity. 54(10). 2417–2432.e5. 38 indexed citations
5.
Lee, Lauren, Yoshiyuki Hizukuri, Paul Severson, et al.. (2021). A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 106(4). 1022–1033. 10 indexed citations
6.
Maziarz, Richard T., Mark J. Levis, Mrinal M. Patnaik, et al.. (2020). Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation. 56(5). 1180–1189. 100 indexed citations
7.
Zeis, Patrice, Xiying Fan, Josip S. Herman, et al.. (2020). In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell Progenitors. Immunity. 53(4). 775–792.e9. 101 indexed citations
8.
Ambinder, Alexander J., Kelly J. Norsworthy, Daniela Hernandez, et al.. (2020). A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. Frontiers in Oncology. 10. 587062–587062. 4 indexed citations
9.
Hernandez, Daniela, et al.. (2019). Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Blood Advances. 3(6). 908–916. 57 indexed citations
10.
Su, Meng, Yu‐Ting Chang, Daniela Hernandez, Richard J. Jones, & Gabriel Ghiaur. (2019). Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment. Journal of Cellular and Molecular Medicine. 23(6). 4111–4117. 14 indexed citations
11.
Stehle, Christina, Daniela Hernandez, & Chiara Romagnani. (2018). Innate lymphoid cells in lung infection and immunity. Immunological Reviews. 286(1). 102–119. 38 indexed citations
12.
Chang, Yu‐Ting, Daniela Hernandez, Gabriel Ghiaur, Mark J. Levis, & Richard J. Jones. (2017). Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs). Blood. 130. 2519–2519. 3 indexed citations
13.
Hernandez, Daniela, Yu‐Ting Chang, Ravi Varadhan, et al.. (2016). Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. Journal of Clinical Investigation. 126(12). 4460–4468. 37 indexed citations
14.
Fathi, Amir T., Traci M. Blonquist, Mark J. Levis, et al.. (2016). A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia. Blood. 128(22). 5218–5218. 4 indexed citations
15.
Hernandez, Daniela, et al.. (2016). Effects of various antiplatelet drugs on ex vivo platelet activation induced by equine herpesvirus type 1. American Journal of Veterinary Research. 77(12). 1366–1373. 3 indexed citations
16.
Norsworthy, Kelly J., Daniela Hernandez, Meng Su, et al.. (2015). RAR-Alpha Targeting Compounds Overcome Bone Marrow (BM) Stromal Protection of AML By CYP26. Blood. 126(23). 2474–2474. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026